Ono Pharmaceutical Co Stock Today
| OPHLY Stock | USD 3.71 0.02 0.54% |
PerformanceOK
| Odds Of DistressLow
|
Ono Pharmaceutical is trading at 3.71 as of the 21st of March 2025; that is 0.54 percent increase since the beginning of the trading day. The stock's open price was 3.69. Ono Pharmaceutical has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 1.47 B outstanding shares. More on Ono Pharmaceutical Co
Moving against Ono Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ono Pink Sheet Highlights
| CEO | Gyo Sagara |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Ono Pharmaceutical Co [OPHLY] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.55 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ono Pharmaceutical's market, we take the total number of its shares issued and multiply it by Ono Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ono Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.47 B outstanding shares.
Ono Pharmaceutical Co has accumulated about 136.18 B in cash with 61.83 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 92.88, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ono Pharmaceutical Probability Of Bankruptcy
Ownership AllocationOno Pharmaceutical owns a total of 1.47 Billion outstanding shares. Roughly 99.97 pct. of Ono Pharmaceutical outstanding shares are held by general public with 0.03 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ono Ownership Details
Ono Pharmaceutical Risk Profiles
| Mean Deviation | 1.2 | |||
| Semi Deviation | 1.41 | |||
| Standard Deviation | 1.64 | |||
| Variance | 2.7 |
Ono Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ono Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Ono Pharmaceutical Corporate Directors
| Hiromu Habashita | Executive Officer, Chief Director of Research | Profile | |
| Katsuji Teranishi | Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | Profile | |
| Toshihiro Tsujinaka | Executive Officer, Senior Director of Oncology in Main Sales Unit | Profile | |
| Hiroshi Ichikawa | Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | Profile |
Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.